

REMARKS

The Examiner rejects claims 11-12, 14 and 18-22 as being anticipated by Meyer et al. Claim 11 has been amended to include the limitations of claim 15 and the substituted hydrocarbon-based group of claim 15 further limited to "an acid substituted" hydrocarbon-based group. Since claim 11 is now allowable by incorporating the limitations of claim 15, cancelled claim 23 has been presented in dependent form as new claim 25 and cancelled claim 24 has been presented as new claim 26 depending on claim 25.


Claims 11-15 and 18-24 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9 of copending application no. 10/069,220. A Terminal Disclaimer is filed concurrently herewith to overcome this rejection.

Referring to the Information Disclosure Statement filed September 24, 2004, FR 2,746,008 describes a composition comprising a combination of at least one Vitamin C derivative and at least one protease inhibitor selected from rutin, mulberry leaf concentrate, Vitamin E acetate and mixtures thereof. This compound is a silane having one silicon atom and two hydroxyl groups but no basic chemical function. Therefore, this document does not describe a composition as claimed in claim 11.

In view of the foregoing, early and favorable action is respectfully requested.

A Petition For Extension Of Time is being filed concurrently herewith.

The Commissioner is hereby authorized to charge any fees due in connection with the present response to Deposit Account 19-4293.

Respectfully submitted,

D. Douglas Price
Reg. No. 24,514

STEPTOE & JOHNSON LLP
1330 Connecticut Ave., N.W.
Washington, D.C. 20036
Tel: (202) 429-3000